BridgeMD
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
EU CTIS ID: 2023-504254-35-00
What this study is testing
Part A: To evaluate safety and tolerability of a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type. Part B: To determine the RP2D of [177Lu]Lu DPI 4452 for each tumor type. Part C: To evaluate the preliminary antitumor activity of [177Lu]Lu DPI-4452 for each tumor type. Part D: To assess the diagnostic concordance between [68Ga]Ga-DPI-4452 PET/CT and the histopathology results of the IDRM. Part E: To assess [68Ga]Ga-DPI-4452 uptake in each tumor type.
- Phase I and Phase II (Integrated)- First administration to humans
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1_Part A: Histologically or cytologically confirmed, unresectable locally advanced or metastatic solid tumors of: -ccRCC; - PDAC; - CRC.
- 3_Part A: Patient ECOG performance status 0-2
- 4_Part A: Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening
- 5_Part A: Adequate blood counts: - Hemoglobin ≥8 g/dL - Absolute neutrophil count (ANC) ≥1.0 × 109/L - Platelets ≥50 × 109/L
- 6_Part A: Adequate hepatic function: - Aspartate or alanine aminotransferase or alkaline phosphatase (AST, ALT, ALP) ≤ 3.0 × upper limit of normal (ULN) (≤ 5.0 ×ULN if patient has liver metastases) - Bilirubin ≤ 1.5 × ULN (a. up to 2.0 × ULN is allowed if the direct bilirubin level is normal, and the elevation is limited to indirect bilirubin b. Up to 5.0 x ULN in case of Gilbert’s Syndrome)
- 7_Part A: Adequate renal function: - For PDAC and CRC patients: estimated glomerular filtration rate (eGFR) >50 mL/min/1.73 m² (as determined by the Chronic Kidney Disease - Epidemiology Collaboration - creatinine [CKD-EPIcr] formula) - For ccRCC patients: eGFR > 40 mL/min/1.73 m²(CKD-EPIcr)
You likely can't join if
- 1_Part A, D, E: Known hypersensitivity to the active substance, to any of the excipients of the DPI 4452, or to radiographic contrast agents
- 19_Part D E: Administration of a radiopharmaceutical with therapeutic intent within a period 6 months prior to injection of [68 Ga Ga DPI-4452]
- 7_Parts B, C: Known hypersensitivity to the active substance, to any of the excipients of the DPI 4452, or to radiographic contrast agents
- 20_Part D,E: Patients who received any systemic antineoplastic therapy for the underlying disease and/or any other investigational study within 28 days or 5 half-life periods (whichever is shorter) prior to injection of [ 68 Ga]Ga-DPI-4452
- 21_Part D, E: Malignant disease, other than that being treated in this study. Exceptions include the following: malignancies that were treated curatively and have not recurred within 2 years prior to screening; treated basal cell or localized squamous skin carcinomas, localized or low grade (e.g., Gleason 3+3 or 3+4 with low prostate specific antigen) prostate cancer, superficial (non-muscle invasive) urothelial cancer, localized thyroid gland microcarcinoma, other in-situ carcinoma, or other malignancy for which patients are not on active antineoplastic therapy.
- 8_Parts B, C: Bladder outflow obstruction or unmanageable urinary incontinence
See the full eligibility criteria
Who can join
- 1_Part A: Histologically or cytologically confirmed, unresectable locally advanced or metastatic solid tumors of: -ccRCC; - PDAC; - CRC.
- 3_Part A: Patient ECOG performance status 0-2
- 4_Part A: Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening
- 5_Part A: Adequate blood counts: - Hemoglobin ≥8 g/dL - Absolute neutrophil count (ANC) ≥1.0 × 109/L - Platelets ≥50 × 109/L
- 6_Part A: Adequate hepatic function: - Aspartate or alanine aminotransferase or alkaline phosphatase (AST, ALT, ALP) ≤ 3.0 × upper limit of normal (ULN) (≤ 5.0 ×ULN if patient has liver metastases) - Bilirubin ≤ 1.5 × ULN (a. up to 2.0 × ULN is allowed if the direct bilirubin level is normal, and the elevation is limited to indirect bilirubin b. Up to 5.0 x ULN in case of Gilbert’s Syndrome)
- 7_Part A: Adequate renal function: - For PDAC and CRC patients: estimated glomerular filtration rate (eGFR) >50 mL/min/1.73 m² (as determined by the Chronic Kidney Disease - Epidemiology Collaboration - creatinine [CKD-EPIcr] formula) - For ccRCC patients: eGFR > 40 mL/min/1.73 m²(CKD-EPIcr)
- 8_Parts B, C: Histologically or cytologically confirmed progressive, unresectable locally advanced or metastatic solid tumors of: -ccRCC; - PDAC; -UC.
- 9_Parts B, C: Measurable disease per RECIST v1.1
- 17_PART B, C: Presence of at least 1 non-irradiated tumor lesion detected at conventional imaging (CT/MRI) documented after or during the last anticancer therapy and within 64 weeks preceding the planned [177Lu]Lu-DPI-4452 [68Ga]Ga-DPI-4452 administration (for scan dated more than 6 weeks prior to C1D1, the Sponsor should be contacted to assess conventional imaging suitability)
- 18_Part B and C: ≥75% of the lesions detected by standard imaging (CT scan, MRI) assessed locally by the Investigator (for Part B) or assessed by central reading (Part C) must be positive by [68Ga]GaDPI-4452 PET. Upon agreement between the Sponsor and Investigator, patients with PDAC and patients with UC with <75% lesion positivity may be eligible if their primary tumor or their biggest tumor lesion as detected by standard imaging (CT scan, MRI) is positive by [68 Ga]Ga- DPI-4452 PET as per local assessment.
- 19_Part B and C: Patients with known central nervous system (CNS) metastasies will be eligible if they are clinically stable, and asymptomatic. Patients must have completed primary CNS therapy more than 4 weeks before treatment start (such as whole brain radiotherapy, stereotactic radiosurgery, or complete surgical resection). Low doses of steroids for the purposes of maintaining neurological integrity (not exceeding of prednisolone 10 mg/day or equivalent) are allowed. For patients with CNS metastasies (or a history of CNS metastasies), baseline and subsequent radiological imaging must include evaluation of the brain (MRI preferred or CT with contrast).
- 10_Parts B, C: Patient ECOG performance status 0-1
- 20_Part D: Patients with Imaging evidence of a single indeterminate renal mass of ≤ 7 cm in largest diameter (tumor stage cT1) on any conventional diagnostic imaging technique, suspicious for ccRCC and planned for total or partial nephrectomy, or interventional diagnostic (cystoscopy and retrograde pyelography or biopsy) within 90 days from planned [68Ga]Ga-DPI-4452 administration;
- 21_Part D, E: Adequate renal function: Estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73 m2 (as determined by the Chronic Kidney Disease – Epidemiology Collaboration - creatinine [CKDEPIcr] formula)
- 22_Part A, B, C, D, E: WOCBP (defined as sexually mature women who have not undergone bilateral tubal ligation, bilateral oophorectomy or hysterectomy or who have not been postmenopausal) must have a negative serum pregnancy test at screening and must not be breastfeeding. Additionally, they must agree to use highly effective methods of contraception from informed consent form (ICF) signature for 6 months after the [68Ga]Ga-DPI-4452 injection (all cohorts) and for 8 months after the last 177 [Lu]Lu-DPI-4452 infusion (part B and C only). Sexual abstinence is acceptable only if it is consistent with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of birth control : •A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A FSH level at screening (>40 IU/L) in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, women will be considered of childbearing potential • Permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy at least 6 months prior to first dosing or documented congenital sterility • Highly effective methods of contraception include combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion/ligation procedures, vasectomized partner, and sexual abstinence during the entire study duration if in adequation with the patient usual lifestyle. Periodic abstinence (e.g., calendar, symptothermal, post-ovulation methods) and withdrawal are not considered as a highly effective method and are not acceptable
- 23_Part A, B, C, D, E: Sexually active men must agree to use a condom during intercourse, refrain from fathering a child during treatment period, and donate sperm for 3 months after the [68Ga]GaDPI-4452 injection (all cohorts) and for 5 months after the last [177Lu]Lu-DPI-4452 infusion (part B and C only) Female partners of childbearing potential must agree to practice sexual abstinence or be under highly effective birth control method for the above mentioned duration.
- Part E: Regardless of lines of treatment, patients with histologically or cytologically confirmed progressive, unresectable locally advanced or metastatic solid tumors of • UC, including MIBC • HNSCC • TNBC • Squamous NSCLC • Any other indication with confirmed CA IX expression, excluding ccRCC, PDAC and CRC, upon Sponsor agreement
- 25_Part E: Presence of at least 1 non-irradiated tumor lesion detected at conventional imaging (CT/MRI) documented within 4 weeks prior to the [68Ga]Ga-DPI-4452 administration (for scans dated more than 4 weeks prior to D1, the Sponsor should be contacted to assess conventional imaging suitability)
- 11_Parts B, C: Life expectancy >6 months
- 12_Parts B, C: Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening
- 13_Parts B, C: Adequate blood counts: - Hemoglobin ≥9 g/dL - ANC ≥1.5 × 109/L - Platelets ≥100 × 109/L
- 14_Parts B, C: Adequate hepatic function: - AST, ALT, ALP ≤3.0×ULN (≤5.0×ULN if patient has liver metastases) - Bilirubin ≤1.5 × ULN (a. up to 2.0 × ULN is allowed if the direct bilirubin level is normal, and the elevation is limited to indirect bilirubin b. Up to 5.0 x ULN in case of Gilbert’s Syndrome)
- 15_Parts B, C: Adequate renal function: - For PDAC, UC patients: eGFR ≥50 mL/min/1.73 m2 (CKD-EPI) - For ccRCC patients: eGFR >40 mL/min/1.73 m2 (CKD-EPI
- 16_Parts B, C: Adequate coagulation: - International normalization ratio or prothrombin time ≤1.5xULN and no history of major thrombotic or clinically relevant major bleeding event in the past 6 months putting the subject at high risk of bleeding during the study as assessed by the Investigator
- 2_Part A, E: Measurable disease as per RECIST v1.1
What rules you out
- 1_Part A, D, E: Known hypersensitivity to the active substance, to any of the excipients of the DPI 4452, or to radiographic contrast agents
- 19_Part D E: Administration of a radiopharmaceutical with therapeutic intent within a period 6 months prior to injection of [68 Ga Ga DPI-4452]
- 7_Parts B, C: Known hypersensitivity to the active substance, to any of the excipients of the DPI 4452, or to radiographic contrast agents
- 20_Part D,E: Patients who received any systemic antineoplastic therapy for the underlying disease and/or any other investigational study within 28 days or 5 half-life periods (whichever is shorter) prior to injection of [ 68 Ga]Ga-DPI-4452
- 21_Part D, E: Malignant disease, other than that being treated in this study. Exceptions include the following: malignancies that were treated curatively and have not recurred within 2 years prior to screening; treated basal cell or localized squamous skin carcinomas, localized or low grade (e.g., Gleason 3+3 or 3+4 with low prostate specific antigen) prostate cancer, superficial (non-muscle invasive) urothelial cancer, localized thyroid gland microcarcinoma, other in-situ carcinoma, or other malignancy for which patients are not on active antineoplastic therapy.
- 8_Parts B, C: Bladder outflow obstruction or unmanageable urinary incontinence
- 9_Parts B, C: Administration of a radiopharmaceutical with therapeutic intent within a period of 6 months prior to injection of [68Ga]Ga-DPI-4452
- 13_Parts B and C: History of active stomach or duodenum ulcer in the last 2 years, history of gastroesophageal reflux disease (GERD) Grade ≥3 according to NCI-CTCAE and/or known active gastro-intestinal infection, any unresolved prior radiation-induced gastrointestinal injury. History of gastro-intestinal toxicities from prior systemic cancer therapy not responding to medical treatment.
- 11_Parts B, C: ongoing treatment with sulfonamides and/or coumarin derivatives (e.g., acenocoumarol, warfarin, phenprocoumon) or any previous CA IX-targeting treatment within 2 weeks (or 5 halflives, whichever is longer) prior to the [68Ga]Ga-DPI-4452 injection and [177Lu]Lu DPI 4452 infusion. Patients on stable therapeutic anticoagulation with low molecular weight heparin or direct acting oral anticoagulants without evidence of previous bleeding complications may be eligible upon agreement between Investigator and Sponsor
- 12_Parts B, C: Prior EBRT to more than 25% of the bone marrow as judged by the Investigator
- 2_Part A: Bladder outflow obstruction or unmanageable urinary incontinence
- 3_Part A, E: Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of [68Ga]Ga-DPI-4452
- 22_Part D,E: Prior EBRT to more than 25% of the bone marrow, as judged by the Investigator
- 23_Part D,E: Inability to stay in the scanner bed with the arms resting out of the thoracic and abdominal fields (i.e., arms alongside the body or raised arm position) for the duration of the scan
- 4_Part A: Previous CA IX-targeting treatment
- 5_Part A: Ongoing treatment with sulfonamides and/or coumarin derivatives (e.g., acenocoumarol, warfarin, phenprocoumon) within 2 weeks (or 5 half-lives, whichever is longer) prior to the [68Ga]Ga-DPI-4452 injection
- 6_part A, E: Prior external beam radiation therapy (EBRT) to more than 25% of the bone marrow, as judged by the Investigator
- 14_Part B,C: For patients included in cohorts with acetazolamide, any contra-indication to acetazolamide according to the local product label, including hypersensitivity to acetazolamide or any of its excipients or any other sulfonamides
- 15_Part D: Renal mass known to be malignant
- 16_Part D: Uncontrolled intercurrent illness or condition, including but not limited to ongoing or active infection, spinal cord compression, uncontrolled psychiatric disorders, or any clinically significant abnormalities detected during screening laboratory tests, ECG test or physical exams that, in the opinion of the Investigator, would adversely affect the participant's ability to participate in the study
- 17_Part D, E: Ongoing treatment with sulfonamides and/or coumarin derivatives (e.g., acenocoumarol, warfarin, phenprocoumon) or any previous CA IX-targeting treatment within 2 weeks (or 5 half-lives, whichever is longer) prior to the [68Ga]Ga-DPI4452 injection
The study team makes the final eligibility decision.
Where it's taking place
- United States
- Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.